Knowledge survey to assess the effectiveness of educational materials among healthcare professionals who prescribe Lemtrada® (alemtuzumab)

Study identification

• EU PAS number:
  EUPAS35547
• Study ID:
  35666
• Official title and acronym:
  Knowledge survey to assess the effectiveness of educational materials among healthcare professionals who prescribe Lemtrada® (alemtuzumab)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  Denmark

  Germany

  Greece

  Italy

  Netherlands

  Norway

  Spain

  United Kingdom
• Study description:
  The overall objective of the survey is to assess descriptively the knowledge level of Healthcare Professionals (HCPs) with regard to educational messages and thus the effectiveness of the educational materials to support the safe use of LEMTRADA:Research questions:1. What is the HCP's understanding and awareness of the risks associated with use of LEMTRADA?2. What is the HCP's knowledge of the key safety messages in the content of the HCP guide and HCP checklist?3. What is the HCP's knowledge and understanding of the risk minimization activities to be undertaken in relation to LEMTRADA?
• Study status:
  Finalised

Research institutions and networks

Institutions

Sanofi

Study timelines

Date when funding contract was signed

Planned: 01/12/2015

Actual: 05/01/2016

Study start date

Planned: 01/12/2015

Actual: 01/03/2016

Data analysis start date

Planned: 01/02/2016

Actual: 01/08/2016

Date of interim report, if expected

Planned: 07/03/2016

Actual: 07/11/2016

Date of final study report

Planned: 06/11/2017

Actual: 05/11/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Sanofi

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

ALEMLC09614